Pipeline
PreDx and Parkinson´s disease
Parkinson’s disease (PD) is a neurodegenerative disorder that affects 1–2% of the population over the age of 65. It is the second most common neurodegenerative disease and the most prevalent movement disorder. By the time PD is diagnosed, 60–70% of the relevant brain neurons have already been affected, leading to symptoms such as tremors, stiffness, and slowed movement.
While there is currently no cure for PD, existing medications can significantly alleviate symptoms. New treatments are in development, but their success depends heavily on the ability to detect the disease at an early stage.
In recent years, seeding amplification assays have emerged as a promising diagnostic tool for PD. In cerebrospinal fluid (CSF), this technique has advanced enough to be considered a valid method for diagnosis. However, there remains a pressing need for a less invasive and more cost-effective diagnostic solution suitable for routine clinical use.
To meet this need, Pre Diagnostics is developing a novel blood-based diagnostic tool for Parkinson’s disease.
Science behind:
(1) Concha-Marambio L. et al., Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid, Nat. protocols. 10.1038/s41596-022-00787-3 (2023).
(2) Oftedal L. et al., Seed Amplification Assay as a Diagnostic Tool in Newly-Diagnosed Parkinson’s, J. of Parkinson´s Dis. 10.3233/JPD-230065 (2023).
